Skip to main content

Table 5 Summary of relevant prospective non-randomised trials (with sample size more than 10) included in the review

From: Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review

Intervention

Dose

Study

N

STS subtypes (%)

Brostallicin

10 mg/m2

Leahy 2007 [33]

43

Multiple

Cisplatin

50 mg/m2

Thigpen 1986 [34]

20

Leiomyosarcoma

Cyclophosphamide

1.5 g/m2

Bramwell 1993 [35, 36]~

18

NS

Dacarbazine

1200 mg/m2

Buesa 1991 [73]

47

Multiple

Docetaxel

100 mg/m2

Kostler 2001 [37]

25

Multiple

Docetaxel

100 mg/m2

Santoro 1999 [38]

37

Multiple

Docetaxel

100 mg/m2

van Hoesel 1994 [39, 40]~

21

NS

Doxorubicin

75 mg/m2

Mouridsen 1987 [41]

23

NS

Etoposide

200-240 mg/m2/day

Crawley 1997 [42]

17

Multiple

Etoposide

130 mg/m2

Dombernowsky 1987 [43]

26

NS

Gefitinib

500 mg

Ray-Coquard 2008 [44]

48

Synovial sarcoma≈

Gemcitabine

1000 mg/m2

Ferraresi 2008 [74]

14

Multiple

Gemcitabine

1000 mg/m2

Hartmann 2006 [45]

15

Multiple

Gemcitabine

1000 mg/m2

Look 2004 [75]

35

Leiomyosarcoma

Gemcitabine

200-250 mg/m2

Spath-Schwalbe 2000 [46]

18

Multiple

Ifosfamide

2 g/m2 for 4d q3w

Antman 1985 [47]

31

Multiple

Ifosfamide

2 g/m2 for 4d q3w

Antman 1989 [48]

94

Multiple

Ifosfamide

1 g/m2 daily until Gr3 granulocytopenia q4w

Babovic 1998 [76]

21

Multiple

Ifosfamide

4 g/m2 for 3d q4w

Le Cesne 1995 [49, 77]~

40

Multiple

Ifosfamide

4 g/m2 for 3d q4w

Nielsen 2000 [78]

13

NS

Ifosfamide

3.5 g/m2 for 4d q3w

Palumbo 1997 [79]

38

Multiple

Ifosfamide

4 g/m2 for 3.5d q3w

Patel 1997 [80]

12

Multiple

Ifosfamide

2g/m2 loading dose followed by 4g/m2 for 3d q3w

Patel 1997 [80]

32

Multiple

Ifosfamide

60 mg/kg for 5d q3-4w

Scheulen 1983 [81]

16

NS

Liposomal doxorubicin

55 mg/m2

Skubitz 2003 [50]

20

Multiple

Liposomal doxorubicin

30-50 mg/m2

Toma 2000 [51]

25

Multiple

Methotrexate

40 mg/m2

Buesa 1984 [52]

37

NS

Paclitaxel

135-175 mg/m2

Palumbo 1997 [53]

12

Multiple

Paclitaxel

200 mg/m2

Patel 1997 [54]

12

Multiple

Paclitaxel

120 mg/m2

Skubitz 1997 [55]

17

Multiple

Sorafenib

400 mg

Bertuzzi 2010 [56, 57]~

61

Multiple

Sorafenib

400 mg

Pacey 2011 [28]

16

Multiple

Sunitinib

50 mg

Decoster 2010 [58]

24

NS

Trabectedin

1.5 mg/m2

Garcia-Carbonero 2004 [59, 60, 82]~

36

Multiple

Trabectedin

1.5 mg/m2

Le Cesne 2005 [83]

104

Multiple

Trabectedin

1.5 mg/m2

Yovine 2004 [61, 84]~

27

Multiple

Biricodar + doxorubicin

B - 120 mg1.5 mg/m2/hr; D – 60 mg/m2

Bramwell 2002 [62]

18

Multiple

Cisplatin + ifosfamide

C – 100 mg/m2 day 2&9; I −2.5 g/m2 for 3d

Budd 1993 [85]

38

Multiple

Cisplatin + vinblastine

C – 50–100 mg/m2 day 1; V – 1.0-1.2 mg/m2 for 5d

Keohan 1997 [63]

18

Multiple

D + IL-2

D – 70 mg/m2; IL-2 - 18 MIU/m2

Le Cesne 1999 [64]

12

NS

Epirubicin + lonidamine

E – 120 mg/m2; I – 150–450 mg

Lopez 1995 [65]

25

Multiple

Etoposide + ifosfamide

E – 200 mg/m2 for 3d; I – 1.5 g/m2 for 3d

Saeter 1995 [86]

11

NS

Etoposide + ifosfamide

E – 50 mg/m2 for 8d; I - 1.5 g/m2 for 6d

Skubitz 1993 [87]

16

Multiple

Gemcitabine + dacarbazine

G – 800–2160 mg/m2; DTIC – 500 mg/m2

Buesa 2004 [66]

22

Multiple

Gemcitabine + dacarbazine

G – 1800 mg/m2; DTIC – 500 mg/m2

Losa 2007 [67]

26

Multiple

Gemcitabine + docetaxel

G – 900 mg/m2; D – 100 mg/m2

Hensley 2002 [88]

16

Leiomyosarcoma

Gemcitabine + docetaxel

G – 900 mg/m2; D – 100 mg/m2

Hensley 2008 [89]

51

Leiomyosarcoma

Gemcitabine + docetaxel

G – 900 mg/m2; D – 100 mg/m2

Montalar 2008 [68]

12

Multiple

Methotrexate + vincristine

M – 5 g/m2; V – 1 mg/m2

Vaughn 1984 [69]

14

NS

VAC + IE

V – 2 mg; A – 70 mg/m2; C – 600 mg/m2; I – 1.8 g/m2; E – 500 mg/m2

Palumbo 1998 [70]

12

NS

C + VC + D + DTIC + IL-2

IL-2 – 18 m units/d, followed by CYVADIC

Gravis 2001 [71]

1

Leiomyosarcoma

D + I + DTIC + IL-2

IL-2 – 18 m units/d, followed by D+I+DTIC

Gravis 2001 [71]

9

Multiple

D + IL-2

IL-2 – 18 m units/d, followed by D

Gravis 2001 [71]

3

Multiple

Carboplatin + etoposide

C – 300 mg/m2; E – 300 mg/m2

Holstein 1996 [72]

8

Multiple

Dacarbazine

1200 mg/m2

Holstein 1996 [72]

14

Multiple

  1. C + VC + D + DTIC + IL-2: Cyclophosphamide + Vincristine + Doxorubicin + Dacarbazine + Interleukin-2; D + IL-2: Doxorubicin + Interleukin-2; D + I + DTIC + IL-2: Doxorubicin + Ifosfamide + Dacarbazine + Interleukin-2; N: Number of Included Patients; n-RCT: Non-Randomised Controlled Trials; VAC + IE: Vincristine + Adriamycin + Cyclophosphamide + Ifosfamide + Etoposide; ~Represents secondary reference; NS: Not Specified; ≈Comprise 4.2% other soft tissue sarcoma.